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OBJECTIVE: To evaluate the hemodynamic and metabolic effects of terlipressin and naloxone in cardiac arrest.
METHODS: Cardiac arrest in rats was induced by asphyxia and maintained for 3.5 minutes. Animals were then
resuscitated and randomized into one of six groups: placebo (n =7), epinephrine (0.02 mg/kg; n= 7), naloxone
(1 mg/kg; n =7) or terlipressin, of which three different doses were tested: 50 mg/kg (TP50; n = 7), 100 mg/kg
(TP100; n= 7) and 150 mg/kg (TP150; n= 7). Hemodynamic variables were measured at baseline and at 10 (T10),
20 (T20), 30 (T30), 45 (T45) and 60 (T60) minutes after cardiac arrest. Arterial blood samples were collected at
T10, T30 and T60.
RESULTS: The mean arterial pressure values in the TP50 group were higher than those in the epinephrine group
at T10 (165 vs. 112 mmHg), T20 (160 vs. 82 mmHg), T30 (143 vs. 66 mmHg), T45 (119 vs. 67 mmHg) and T60 (96
vs. 66.8 mmHg). The blood lactate level was lower in the naloxone group than in the epinephrine group at T10
(5.15 vs. 10.5 mmol/L), T30 (2.57 vs. 5.24 mmol/L) and T60 (2.1 vs. 4.1 mmol/L).
CONCLUSIONS: In this rat model of asphyxia-induced cardiac arrest, terlipressin and naloxone were effective
vasopressors in cardiopulmonary resuscitation and presented better metabolic profiles than epinephrine.
Terlipressin provided better hemodynamic stability than epinephrine.
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& INTRODUCTION
Survival rates and neurologic outcomes among patients
who experience cardiac arrest (CA) are poor (1). Patients
with an initial asystole rhythm have a worse prognosis than
patients with ventricular fibrillation (VF) (2,3). Epinephrine
is the recommended and most widely used vasopressor in
this situation, although there is evidence that it increases
oxygen consumption, reduces subendocardial perfusion (4)
and causes severe myocardial dysfunction following the
return of spontaneous circulation (ROSC) (5).
In addition, recent evidence suggests that epinephrine
worsens perfusion in the cerebral microcirculation and
increases the severity of cerebral ischemia during cardiopul-
monary resuscitation (CPR) (6,7). In a previous study, the use
of epinephrine increased mortality in an experimental
asphyxia-induced CA model (8). In the single published
placebo-controlled human study, epinephrine increased the
ROSC rate but was not better than a placebo with regard to
neurological outcome or survival to discharge (9).
Two recent studies that used terlipressin to treat pediatric
cardiac arrest (in a total of 12 children) produced encoura-
ging results (10,11). However, terlipressin did not increase
the rate of ROSC in two other recent experimental studies
(12,13).
Studies that have used naloxone during CPR have
produced conflicting results (14-24). The mechanism under-
lying the effect of naloxone during CPR remains unclear.
One hypothesis is that hypoxia activates the endogenous
opioid system, which is involved in the respiratory control
system, stimulates catecholamine release and increases
sympathetic nerve activity, thereby elevating heart rate
and blood pressure (17). In addition, naloxone has possible
anti-arrhythmic effects and ameliorates cardiac function,
thereby most likely improving post-resuscitation myocar-
dial dysfunction (21). Finally, naloxone has immunomodu-
latory effects and a possible protective role in postischemic
heart injuries (21).
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Therefore, the current study was designed to evaluate the
effects of terlipressin and naloxone in an experimental
model of asphyxia-induced cardiac arrest in rats. The main
hypothesis was that these drugs could provide better
hemodynamic and/or metabolic profiles in the first hour
post-CA than the standard treatment with epinephrine.
& MATERIALS AND METHODS
This was a randomized, blinded, placebo-controlled
experimental study that was approved by the Institutional
Animal Investigation Committee and was conducted in
accordance with the ARRIVE guidelines (Animals in
Research: Reporting In Vivo Experiments) (25) and
Utstein-style guidelines for uniform reporting of laboratory
CPR research (26). The animals were managed in accor-
dance with the Brazilian College of Animal Experimentation
and National Institutes of Health Guidelines.
Animal preparation
Adult male Wistar rats with an average weight of 399 g
(range: 340 to 445 g) were obtained from the Central Animal
Laboratory of the School of Medicine and anesthetized with
intraperitoneal injections of urethane (0.5 mg/kg) and
ketamine (50 mg/kg). The proximal trachea was surgically
dissected, and a 14-gauge cannula was inserted 10 mm into
the trachea to the larynx. Mechanical ventilation was
performed with a respiratory rate of 85 cycles/minute, tidal
volume of 6 mL/kg, inspired oxygen fraction of 100% and
positive end-expiratory pressure of 1 cm H2O (Rodent
Ventilator, model 683, Harvard Apparatus Inc., Natick,
MA, USA). A catheter was inserted through the jugular vein
and directed toward the right atrium to facilitate drug
administration and volume replacement. For blood pressure
measurement, the left femoral artery was cannulated, and a
catheter was introduced. The catheters were connected to
pressure transducers that were coupled to a calibrated
preamplifier (Stemtech Inc., GPA-4 model 2, Menomonee
Falls, WI, USA) and a computerized data acquisition system
(DATAQ Instruments Inc., Akron, OH, USA). Systemic
hemodynamic measurements were simultaneously recorded
beat by beat. Measurements were taken at baseline and at the
five following time points after CA: the 10th (T10), 20th (T20),
30th (T30), 45th (T45) and 60th (T60) minutes. Monitoring
during the experiment included the following:
N Electrocardiogram: recorded continuously with two
subcutaneous leads.
N Mean arterial pressure (MAP, mmHg).
N Temperature (rectal probe): temperature was maintained
between 36 and 37 C˚ throughout the experiment using a
passive external warming method (infrared lamp).
Vasopressors
The epinephrine dose was 0.02 mg/kg. Although some
recent studies have used higher doses of epinephrine (0.04
to 0.05 mg/kg), doses higher than 0.03 mg/kg are asso-
ciated with increased rates of myocardial dysfunction,
neurological injury and a poor prognosis (27-29). The
chosen naloxone dose was 1 mg/kg because lower doses
have been associated with lower ROSC rates (15) and higher
doses have not been demonstrated to be beneficial (19). The
chosen terlipressin doses were extrapolated from pediatric
studies of CA (10,11). In these pediatric series (total of 12
patients), 10-20 mg/kg terlipressin was administered follow-
ing the administration of a few doses of epinephrine.
Therefore, when terlipressin was used alone, we chose
higher doses (50, 100 and 150 mg/kg). All of the syringes
were visually identical and contained 1 mL of fluid.
Asphyxia-induced cardiac arrest and resuscitation
A preparation and control phase of the experiment was
performed to design a CA model (in anoxia) that had an
ROSC rate of at least 50% with the placebo and approxi-
mately 100% with epinephrine. Several anoxia durations
were studied (4 to 10 minutes). We observed that by
defining a total anoxia time rather than a total CA time, the
animals would be subjected to different CA durations.
Therefore, our model characterized the exact time at which
CA began; it measured the total time of arrest and not the
total time of anoxia.
After the surgical preparation and hemodynamic stabili-
zation of the animal, the trachea was obstructed to induce
CA, which was defined as the loss of aortic pulsation and
MAP ,15 mmHg. After CA was confirmed, the animals
were maintained in asphyxia for 3.5 additional minutes.
Subsequently, the rats were resuscitated following standard
procedures:
N Saline solution (SS) or one of the vasopressor drugs was
administered (all in similar, standardized 1-mL syr-
inges), which was followed by a flush of 0.5 mL of SS;
both were given directly through a central venous
catheter.
N Chest compressions (200/minute) were performed for
all of the groups by a single researcher who was blinded
to the administered vasopressor. The researcher was
guided by an audio device (to ensure the correct
compression frequency), and MAP was monitored and
maintained at .30 mmHg.
N The animal was ventilated with 100% FiO2; the respira-
tory rate was 70 cycles/min, and the tidal volume was
8 mL/kg.
ROSC was considered to have occurred when MAP
remained .50 mmHg for a minimum of 5 consecutive
minutes. Resuscitation efforts were discontinued in the
absence of ROSC after 5 minutes of chest compressions.
A neuromuscular blockade was performed with pancur-
onium at 15 and 37 minutes after cardiac arrest. The dose
was 0.5 mg/kg.
Arterial blood samples were collected at baseline and at
T10, T30 and T60. Analyses were performed immediately
after each collection and consisted of measurement of
arterial blood gases (pH, pO2, pCO2, oxygen saturation,
bicarbonate and base excess), sodium, potassium, hemoglo-
bin, hematocrit, glucose and lactate. All of the examinations
were performed using the same equipment (Radiometer
ABL 835 Flex, Radiometer Medical ApS, Bronshoj,
Denmark).
Statistical analysis
A database was created using Data Entry 4.0 software
using the double-entry system. A statistical analysis was
performed using PASW Statistics (18.0 for Macintosh). The
qualitative data were expressed as frequencies and percen-
tages, and the numerical data were described as mean
CLINICS 2013;68(8):1146-1151 Terlipressin and naloxone in cardiac arrest
Martins HS et al.
1147
values and standard deviations. The normal distribution of
data was confirmed using the Kolmogorov-Smirnov test. To
compare the mean values in the baseline variables, we used
a one-way ANOVA. The ROSC analysis was performed
using Fisher’s exact test, and a post-hoc analysis was
performed using the Bonferroni test. Two-tailed p,0.05
was considered significant.
& RESULTS
The final sample consisted of 42 animals, which were
randomized into one of the following groups: placebo
(n= 7), epinephrine (EPI; n= 7), naloxone (Nalo; n=7),
terlipressin 50 mg/kg (TP50; n= 7), terlipressin 100 mg/kg
(TP100; n= 7) or terlipressin 150 mg/kg (TP150; n= 7).
The groups were homogeneous, and there was no
significant difference among them regarding hemodynamic
and laboratory variables (Table 1). ROSC occurred in four of
the seven animals (57%) in the placebo group and in 100% of
the animals in the vasopressor groups (35 animals;
p= 0.002). The time between the induction of anoxia and
the onset of CA was 246.1 seconds (¡67.4 sec), as shown in
Table 2. The total time of hypoxia was not different between
the groups and was calculated by adding the time between
the onset of anoxia and CA to the time during which the
animals remained in CA (3.5 min). During the first hour of
the experiment, four animals died: two in the EPI group,
one in the TP100 group and one in the TP150 group.
Mean arterial pressure and blood tests
The animals in the terlipressin groups had higher MAP
values than animals in the epinephrine group (Table 3).
However, the MAP levels were not significantly different
when naloxone was compared with epinephrine.
The TP50 and naloxone groups had lower blood lactate
values than the epinephrine group (Table 4). The best
metabolic profile was observed in the naloxone group, and
the worst profile was observed in the epinephrine group
(Tables 5 and 6).
& DISCUSSION
Our findings suggest that terlipressin and naloxone could
be used as alternatives to epinephrine or vasopressin in the
treatment of CA with a nonshockable rhythm (asystole/
PEA). Terlipressin had a better hemodynamic metabolic
profile than epinephrine. Naloxone was the vasopressor
with the best metabolic profile.
In the present study, we chose three different terlipressin
doses to evaluate their effects in resuscitation. The doses
were compared both among themselves and with epinephr-
ine and a placebo. This is the first study that aimed to study
drugs (and dosages) of alternatives to epinephrine in the
treatment of cardiac arrest.
In the context of asystole, our data suggest that very high
doses (greater than or equal to 100 mg/kg) were associated
with worse outcome and even worse metabolic profiles,
perhaps because of the greater time necessary to obtain the
ROSC. Moreover, 50 mg/kg terlipressin produced a more
favorable profile than epinephrine in the first hour follow-
ing ROSC. This favorable hemodynamic profile of terlipres-
sin may be related to its increased vasopressor effect and its
long duration of action (4 to 6 hours). Only two randomized
studies have been published that used terlipressin as a
vasopressor during CPR. Ovalle evaluated terlipressin in a
pig model of ventricular fibrillation (13) and found that
terlipressin did not differ from the placebo regarding effects
on coronary perfusion pressure, and low rates of ROSC
Table 1 - Baseline variables of the different groups
Variable Placebo (n=7) Epi (n=7) Nalo (n=7) TP50(n=7) TP100(n=7) TP150(n=7) p-value
Weight (g) 405¡29 386¡25 417¡28 404¡41 390¡29 387¡33 0.37
Heart rate 380¡56 358¡65 384¡37 376¡80 419¡98 408¡65 0.65
MAP (mm Hg) 106¡10 120¡17 110¡14 108¡13 121¡16 106¡11 0.16
Hb (g/dL) 16.4¡0.7 16.2¡0.5 16.3¡0.9 16.7¡0.7 16.8¡0.7 15.9¡0.9 0.23
Ht (%) 50.2¡2.3 49.8¡1.6 50¡2.7 51¡2.1 51¡2.2 49¡2.6 0.24
Na+ (mmol/L) 139¡2.6 137¡1.8 138¡2.6 137¡2.2 139¡3.2 137¡1.7 0.33
K+ (mmol/L) 3.9¡0.2 4.0¡0.3 4.3¡0.3 4.2¡0.2 4.1¡0.4 4.3¡0.5 0.43
Glucose (mg/dL) 208¡30 222¡40 212¡20 212¡29 216¡38 207¡31 0.93
paO2 (torr) 343¡83 316¡80 298¡54 338¡68 367¡60 294¡94 0.42
SatO2 (%) 97.8¡0.2 97.7¡0.3 97.7¡0.1 97.7¡0.5 97.7¡0.2 97.4¡0.5 0.79
pCO2 (torr) 41¡6.3 41¡6.5 39¡6.4 39¡3.7 39¡2.2 41¡3.2 0.96
pH 7.36¡0.04 7.36¡0.04 7.38¡0.05 7.36¡0.03 7.38¡0.03 7.37¡0.06 0.94
Bic (mmol/L) 22.8¡3.1 22.9¡2.1 22.6¡1.3 22.4¡1.4 23.3¡1.6 23.4¡1.1 0.91
Base excess 21.9¡2.8 21.6¡1.8 21.7¡1.2 22¡1.5 21.1¡1.8 2.9¡1 0.78
Lactate (mmol/L) 2.68¡0.58 2.51¡0.39 2.33¡0.55 2.44¡0.63 1.9¡0.44 2.6¡0.43 0.14
The values represent the mean ¡ SD.
Table 2 - Times (sec) between the onset of anoxia and cardiac arrest, time from cardiopulmonary resuscitation to the
return of spontaneous circulation and the total time during which the animals remained in hypoxia
Variable Placebo Epi Nalo TP50 TP100 TP150 p-value
Onset of anoxia to CA 272¡70 243¡71 235¡40 233¡71 236¡79 250¡69 0.55
From CPR to ROSC 114¡40a 79¡43 86¡27 110¡57 125¡59 142¡77 0.16
Total hypoxia 482¡70 453¡71 445¡40 443¡71 446¡79 460¡69 0.55
The values represent the mean ¡ SD.
aData from four animals (three animals did not present ROSC).
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were observed in both groups. As a monotherapy, perhaps
the low dose of terlipressin (10 to 20 mg/kg) chosen explains
these findings. In a pediatric model, ROSC was observed in
three of 15 animals receiving standard doses of epinephrine,
four of 15 animals receiving high-dose epinephrine, one of
15 animals receiving terlipressin and seven of 15 animals
receiving both epinephrine and terlipressin (12). The
differences between the groups were not significant. The
use of propofol in a model of hypoxia-induced CA may not
be desirable and may have contributed to the low frequency
of ROSC in that study, which was much lower than the
expected rates in pediatric CA models. Furthermore, a low
dose of terlipressin (10 to 20 mg/kg) was chosen based on
two pediatric series (10,11). The fact that the children in
these studies had already received several epinephrine
doses prior to receiving terlipressin may not have been
considered when the dose of terlipressin was chosen as the
only vasopressor in this model of CPR. Lower terlipressin
doses have been shown to be effective in the treatment of
septic shock (30-32). However, when used as a single drug
in CA, higher doses of terlipressin may be necessary
(.20 mg/kg). Our findings confirm that terlipressin is a
fast-acting vasopressor whose initial effect is inherent and
occurs before the endothelial conversion of terlipressin to
lysine-vasopressin (33). In addition, we demonstrated that
animals that received terlipressin maintained a significantly
higher MAP than those that received epinephrine or
vasopressin throughout the post-CA period.
No significant differences in MAP were observed with
different doses of terlipressin. However, based on the values
of lactate, bicarbonate and base excess, animals receiving a
50 mg/kg dose had a more favorable metabolic profile than
those receiving 100 mg/kg or 150 mg/kg.
In other studies using naloxone in rat asphyxia models,
the ROSC rates were similar to those obtained with
epinephrine (seven of eight animals in each group) (16);
there was a trend toward higher ROSC rates at a dose of
1 mg/kg compared with 0.5 mg/kg of naloxone (1 mg/kg:
seven of eight animals; 0.5 mg/kg: three of eight animals)
(15). In addition, the combination of epinephrine and
naloxone decreased the time that was required to attain
ROSC during CPR (naloxone plus epinephrine: 133 sec vs.
epinephrine: 206 sec; p,0.01) (23,24). However, it is difficult
to interpret this evidence because of methodological
problems in these studies. The international recommenda-
tions for research in CA (Utstein-style guidelines) were not
followed, so it was not possible to assess similarities (or
differences) between the animals regarding important
baseline variables, and the animals were resuscitated with-
out oxygen. Neither laboratory nor arterial blood gas values
were monitored before, during or after CA. Finally, the
epinephrine doses (0.04 to 0.05 mg/kg) were higher than
the currently recommended doses.
In our study, all animals that were resuscitated with
naloxone had ROSC and survived through the first hour
following CA. The MAP curves in the rats receiving
naloxone were intermediate between those in rats receiving
terlipressin (better) and epinephrine (worse). Little is known
about the possible benefits of naloxone in the treatment of
CA. In the cardiovascular system, naloxone may increase
sympathetic nervous system activity (34,35), which may
increase heart rate and blood pressure. Naloxone could also
act as an antiarrhythmic (36), and it could even attenuate
myocardial dysfunction after CA (37). Our study is the first
to show that naloxone has a favorable profile regarding
bicarbonate, base excess and lactate levels when it is used as
a vasopressor in CA. These results cannot be attributed to
MAP and may instead be intrinsic to the vasopressor. Our
Table 3 - Mean arterial pressure: comparisons of the
groups vs. time
Groups MAP (mmHg)
T10 T20 T30 T45 T60
Epi 112¡25 82¡25 66¡9 67¡12 66.8¡12
Nalo 138¡36 113¡24 97¡25 85¡24 86¡24
TP50 165¡18a 160¡7b 143¡10b 119¡19b 96¡16
TP100 156¡42 154¡11b 124¡18b 112¡8a 95¡9
TP150 170¡11a 155¡12b 149¡16b 120¡28b 101¡25
p-valuec 0.016 0.000 0.000 0.003 0.088
a: p,0.05 (compared with the epinephrine group).
b: p,0.01 (compared with the epinephrine group).
c: ANOVA between groups.
Table 4 - Blood lactate: comparisons of the groups vs.
time
Groups Blood lactate (mmol/L)
T10 T30 T60
Epi 10.5¡3.7 5.24¡3.2 4.1¡2.2
Nalo 5.15¡1.1b 2.57¡0.9a 2.1¡0.9a
TP50 6.6¡1.2b 2.57¡0.4a 2.05¡0.4a
TP100 6.7¡1.3a 3.88¡1.7 2.46¡0.3
TP150 7.34¡1.5 3.67¡0.6 2.84¡0.8
p-value* 0.0008 0.039 0.029
a: p,0.05 (compared with the epinephrine group).
b: p,0.01 (compared with the epinephrine group).
c: ANOVA between groups.
Table 5 - Base excess: comparisons of the groups vs. time
Groups Base excess (mmol/L)
T10 T30 T60
Epi 216.6¡3.5 210.9¡5.2 212¡7.4
Nalo 29.7¡1.7b 26.9¡2.9a 26.7¡2.6
TP50 211.8¡1.8b 29¡1.8 28.8¡1.9
TP100 213.1¡1.5 212.6¡2.1 210.9¡1.5
TP150 213.9¡1.7 211.7¡1.2 210.5¡2.2
p-value* 0.0001 0.0007 0.107
a: p,0.05 (compared with the epinephrine group).
b: p,0.01 (compared with the epinephrine group).
c: ANOVA between groups.
Table 6 - Bicarbonate: comparisons of the groups vs. time
Groups Bicarbonate (mmol/L)
T10 T30 T60
Epi 8.1¡4.5 16.1¡3.6 14.7¡6.1
Nalo 18¡1.6b 19¡2.6a 19.2¡2.6
TP50 16.4¡1.7a 17.3¡1.9 16.9¡1.9
TP100 14.5¡1.1 14.2¡1.7 15.1¡1.3
TP150 14.3¡0.9 15.1¡1.1 16.4¡2.1
p-value* 0.017 0.006 0.152
a: p,0.05 (compared with the epinephrine group).
b: p,0.01 (compared with the epinephrine group).
c: ANOVA between groups.
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results are consistent with a previous finding that naloxone
has a protective effect in ischemia by restoring mitochon-
drial activity and energy metabolism (38).
The strengths of our study include the fact that it was
designed and performed with a uniform, reproducible
sample and control of important variables associated with
the prognosis of CA in asystole. Randomization produced
homogeneous groups. The group allocation in this study
was conducted in a blinded fashion. The measurement of
the hemodynamic variables and blood tests were performed
at several different intervals, both at baseline and during the
experiment, which allowed a temporal analysis of the
differences between the groups at different times (not only
at a single time point). Resuscitation was performed using a
standardized method, which included strict control of MAP
levels during chest compressions. We defined the exact time
that the animal remained without circulation (3.5 min).
Therefore, this model can be used to study different stages
of CA, and it allows investigators to adjust the time without
effective circulation according to the intended research
goals.
Despite these encouraging results, it is important to
analyze these data with caution. The study was not
designed to show any differences in the rates of ROSC
between epinephrine and other drugs. Such an analysis may
require a larger sample and a longer absence of circulation.
The experiment evaluated a specific duration of CA, and the
results could be different in protocols with longer-lasting
CA. Furthermore, anesthesia with both ketamine and
urethane can potentially interfere in epinephrine metabo-
lism, thereby causing hemodynamic variations that may
have affected the results. It is also possible that other agents,
such benzodiazepines, etomidate and barbiturates, could
have less interference. Nevertheless, most published studies
have used ketamine and urethane. Finally, it is known that
studies that are performed during CPR maneuvers in
animals are often not confirmed in clinical trials.
This is the first study that aimed to study terlipressin in
different dosages as an alternative to epinephrine in the
treatment of cardiac arrest. Based on these results, new
studies will be developed to compare the effects of
terlipressin (50 mg/kg) and epinephrine in a pig model of
cardiac arrest. Furthermore, lower doses of naloxone in
association with terlipressin or epinephrine will be evalu-
ated.
In this hypoxia-induced rat CA model, terlipressin and
naloxone were effective vasopressors in resuscitation and
produced better metabolic profiles than epinephrine.
Terlipressin administration resulted in significantly better
hemodynamic stability in the first hour following CA
compared with epinephrine. Among the vasopressors that
were studied in this experiment, naloxone had the best
metabolic profile.
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